Autologous Anti-CD5 CAR T-lymphocytes MB-105

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of genetically modified autologous T-cells expressing a chimeric antigen receptor (CAR) directed against cluster of differentiation 5 (CD5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR T-lymphocytes MB-105 target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells and overexpressed on various B- and T-cell malignancies.

**Synonyms:** - Autologous Anti-CD5 CAR T-cells MB-105 - Autologous Anti-CD5 CAR-T Cells MB-105 - Autologous CD5-specific CAR T-cells MB-105 - Autologous CD5-targeted CAR-T cells MB-105 - Autologous CD5CAR-expressing T-lymphocytes MB-105 - MB 105 - MB-105 - MB105